Immunoglobulin M oligoclonal bands: Biomarker of targetable inflammation in primary progressive multiple sclerosis

@article{Villar2014ImmunoglobulinMO,
  title={Immunoglobulin M oligoclonal bands: Biomarker of targetable inflammation in primary progressive multiple sclerosis},
  author={Luisa Mar{\'i}a Villar and Bonaventura Casanova and Nadia Ouamara and Manuel Comabella and Farzaneh Jalili and David Leppert and Clara de Andr{\'e}s and Guillermo Izquierdo and R. Garc{\'i}a Arroyo and Timucin Avşar and Sergey Vladimirovich Lapin and Trina A. Johnson and Xavier Montalban and {\'O}scar Fern{\'a}ndez and Roberto {\'A}lvarez-Lafuente and Donna L. Masterman and Mar{\'i}a I. Garc{\'i}a‐S{\'a}nchez and Francisco Coret and Aksel Siva and Evgeniy Evdoshenko and Jos{\'e} C. {\'A}lvarez-cerme{\~n}o and Amit Bar-Or},
  journal={Annals of Neurology},
  year={2014},
  volume={76}
}
To identify a biomarker distinguishing patients who, despite a primary progressive multiple sclerosis (PPMS) clinical course, may nonetheless benefit from immune therapy. 
Intrathecal Immunoglobulin M Synthesis is an Independent Biomarker for Higher Disease Activity and Severity in Multiple Sclerosis
TLDR
This large study supports the value of intrathecal IgM synthesis as an independent biomarker of disease activity and severity in relapsing MS.
Multiple sclerosis: Genetic variability affects CNS IgG production in MS
Local synthesis of IgG in the CNS is present in >90% of patients with multiple sclerosis (MS), and is considered a hallmark of the disease. A recent study has discovered genetic factors associated
Anti‐SPAG16 antibodies in primary progressive multiple sclerosis are associated with an elevated progression index
TLDR
Whether anti‐SPAG16 antibody levels differ between MS subtypes (relapsing−remitting, RR; primary or secondary progressive, PP, SP) and whether antibody positivity is associated with clinical characteristics is investigated.
Rituximab treatment for multiple sclerosis
TLDR
Current evidence on mechanisms of action, efficacy, safety, tolerance and other clinical aspects of rituximab in the treatment of MS are summarized and discussed.
Treating primary-progressive multiple sclerosis: potential of ocrelizumab and review of B-cell therapies
TLDR
The involvement of B-cells in MS pathogenesis, current progress of currently available and investigational biologics, with focus on ocrelizumab, and future prospects for B-cell therapy in PPMS are discussed.
The Role of B Cells in Primary Progressive Multiple Sclerosis
The success of ocrelizumab in reducing confirmed disability accumulation in primary progressive multiple sclerosis (PPMS) via CD20-targeted depletion implicates B cells as causal agents in the
Lipid‐specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab
TLDR
This work explored whether the presence of lipid‐specific immunoglobulin M oligoclonal bands in cerebrospinal fluid (CSF; IgM bands), a recognized marker of highly inflammatory MS, may identify individuals better able to counteract the potential immunosuppressive effect of natalizumab and hence be associated with a reduced risk of developing PML.
The role of B cells in the immunopathogenesis of multiple sclerosis
TLDR
The role of different antibody‐dependent and antibody‐independent functions of B cells in MS disease activity and progression are discussed, proposing new therapeutic strategies for the optimization of B‐cell targeting treatments.
Intrathecal IgM as a Prognostic Marker in Multiple Sclerosis
TLDR
The combined evidence from the current literature suggests that intrathecal IgM is a negative prognostic marker that identifies patients with CIS who have a higher risk of converting to CDMS and patients with relapsing–remitting MS (RRMS) with aHigher risk of a more aggressive disease course.
...
...

References

SHOWING 1-10 OF 47 REFERENCES
Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double‐blind placebo‐controlled multicenter trial
Rituximab, a monoclonal antibody selectively depleting CD20+ B cells, has demonstrated efficacy in reducing disease activity in relapsing‐remitting multiple sclerosis (MS). We evaluated rituximab in
Multiple sclerosis with and without CSF bands: Clinically indistinguishable but immunogenetically distinct
TLDR
Swedish patients with multiple sclerosis with and without oligoclonal bands in the CSF constitute distinct subpopulations, clinically and immunogenetically, and the HLA-DRB1 genotyping results suggest that OCB-positive and O CB-negative MS are Immunogenetically distinct.
Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double‐blind, placebo‐controlled trial
TLDR
To determine whether glatiramer acetate slows accumulation of disability in primary progressive multiple sclerosis, a new drug is developed that acts as a ‘spatially aggregating agent’ to reduce the risk of disease progression.
Immunological mechanisms that associate with oligoclonal IgM band synthesis in multiple sclerosis.
Lipid-specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis
TLDR
The presence of lipid-specific immunoglobulin M bands in CSF predicts a more adverse long-term outcome in patients with MS; it may define a subset of patients who might benefit from aggressive treatment during the early phase of the disease.
Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS.
TLDR
The presence of intrathecal anti-myelin lipid IgM antibodies is a very accurate predictor of aggressive evolution in MS and the relationship between specificity and disease evolution is explored.
Primary progressive versus relapsing-onset multiple sclerosis: presence and prognostic value of cerebrospinal fluid oligoclonal IgM
TLDR
This study confirms that, in relapsing-onset MS patients, the presence of CSF OCIgM at onset predicts a worse disease course, and suggests that heterogeneous pathogenetic mechanisms may be involved in the different MS forms.
Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis.
TLDR
In subjects with multiple sclerosis, B cells are critical for T-cell trafficking into the central nervous system and may alter the process by influencing chemokine production within the central nerve system.
Oligoclonal bands and cerebrospinal fluid markers in multiple sclerosis: associations with disease course and progression
TLDR
OCB positivity and elevated total CSF IgG and protein were moderately associated with a PPMS disease course, but not disease progression, suggesting a testing bias.
Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis
TLDR
The follow‐up of a group of relapsing‐remitting MS patients for a longer time to evaluate whether the ITMS implies a poor prognosis, and the presence of oligoclonal IgM bands in cerebrospinal fluid is an unfavorable prognostic marker in MS.
...
...